Godecke Aktiengesellschaft

Warner-lambert Company

Goedecke Aktiengesellschaft

Wolfgang Steinbrecher

Gerhard Satzinger

Manfred F Herrmann

Johannes Hartenstein

Edgar Fritschi

Karl Mannhardt

Bernd Wagner

Heinrich Bahrmann

Hartmut Osswald

Wolfgang Dieter Herrmann

Volker Ganser

Jorgen Kleinschroth

Dieter Muster

The present invention provides 1,6-naphthyridine derivatives of formula ##STR1## wherein R.sup.1 is an unsubstituted or substituted aromatic or heteroaromatic ring or an unsubstituted or substituted condensed aromatic or heterocyclic ring system, R.sup.2 is a straight-chained or branched alkyl radical containing up to 4 carbon atoms, a benzyl radical or a straight-chained or branched, substituted or unsubstituted aminoalkyl radical containing up to 8 carbon atoms, R.sup.3 is a hydrogen atom, a straight-chained or branched alkyl radical or an alkoxycarbonyl radical, in each case containing up to 4 carbon atoms, R.sup.4 is a straight-chained or branched hydrocarbon radical containing up to 21 carbon atoms, which can also contain oxygen, sulphur, nitrogen or halogen atoms and is optionally substituted by carbocyclic or heterocyclic ring systems, or is an amino, cyano, formyl, halogenomethyl or dihalomethyl radical and R.sup.5 is an alkoxycarbonyl radical or an unsubstituted or substituted carboxamide radical with, in each case, up to 21 carbon atoms which can also contain oxygen, sulphur or nitrogen atoms and is optionally substituted by carbocyclic or heterocyclic ring systems or is a carboxyl or cyano group as well as the pharmaceutically acceptable salts thereof. The compounds are useful for blood vessel diseases. The present invention also provides processes for the preparation of these 1,6-naphthyridine derivatives, pharmaceutical compositions containing them, and methods for using them.

1,6-naphthyridine derivatives

The invention is concerned with partially new compounds of the general formula ##STR1## wherein R.sup.1 is a hydrogen atom or an alkyl group with up to four carbon atoms and R.sup.2 a substituted phenyl radical and the pharmacologically acceptable salts thereof. The compounds can be prepared according to known procedures and show surprisingly a cardiovascular efficacy. They are capable of decompensating cardiac insufficiencies to a large extent. In addition to the new compounds, claim is also made for pharmaceutical compositions which contain compounds according to the general formula and their application for controlling cardiac and vascular diseases.

3-aryl-3-pyrroline derivatives

The present invention provides 5,6;8,9-tetrahydro-7H-dibenz(d,f)azonine derivatives of the formula: ##STR1## wherein R.sup.1 and R.sup.2, which are the same or different, are hydrogen or halogen atoms or lower alkyl or alkoxy radicals, R.sup.3 is a hydrogen atom or a lower alkyl radical, R.sup.4 is a hydrogen atom or a lower alkyl or alkanoyl radical and n is 1 or 2; and the pharmaceutically acceptable salts thereof formed with inorganic and organic acids; but excluding 6-benzyl-2,12-dimethoxy-1-hydroxy-7-methyl-5,6;8,9-tetrahydro-7H-dibenz(d, f)azonine in which case R.sup.1, R.sup.2 and R.sup.4 are hydrogen, n is 1 and R.sup.3 is methyl. The lower alkyl, alkanoyl and alkoxy radicals are straight chained or branched radicals containing 1 to 5 carbon atoms. The present invention also provides a process for the preparation of these compounds, as well as pharmaceutical compositions containing them.

5,6;8,9-Tetrahydro-7H-dibenz(d,f)azonines

The invention discloses (+)-(3-methyl-4-oxo-5N-piperidinothiazolidin-2-ylidene)acetic acid esters and a process for their preparation. The process provides the dextrorotatory isomers substantially free from the corresponding levorotatory isomers. Antihypertensive pharmaceutical compositions comprising the dextrorotatory esters and methods for using said compositions are also disclosed.

(+)-(3-Methyl-4-oxo-5N-piperidinothiazolidin-2-ylidene)acetic acid

Growing community of inventors

Gundelfingen, Germany

Wolfgang Steinbrecher